Wells Fargo & Company MN increased its stake in Coherus BioSciences, Inc. (NASDAQ:CHRS) by 27.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,863 shares of the biotechnology company’s stock after buying an additional 6,245 shares during the period. Wells Fargo & Company MN owned 0.06% of Coherus BioSciences worth $611,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the stock. Tudor Investment Corp Et Al boosted its stake in Coherus BioSciences by 34.9% in the fourth quarter. Tudor Investment Corp Et Al now owns 14,396 shares of the biotechnology company’s stock worth $405,000 after buying an additional 3,726 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of Coherus BioSciences by 0.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 14,589 shares of the biotechnology company’s stock worth $411,000 after buying an additional 130 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Coherus BioSciences by 1.3% in the first quarter. Nationwide Fund Advisors now owns 33,982 shares of the biotechnology company’s stock worth $719,000 after buying an additional 421 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Coherus BioSciences during the fourth quarter worth about $1,048,000. Finally, Thrivent Financial for Lutherans purchased a new stake in shares of Coherus BioSciences during the fourth quarter worth about $1,609,000. 73.35% of the stock is owned by institutional investors and hedge funds.

Coherus BioSciences, Inc. (NASDAQ CHRS) traded down 0.39% during midday trading on Friday, hitting $12.70. The stock had a trading volume of 284,864 shares. The stock’s market cap is $651.36 million. The company’s 50 day moving average price is $14.27 and its 200-day moving average price is $20.24. Coherus BioSciences, Inc. has a 52-week low of $12.50 and a 52-week high of $31.98.

Coherus BioSciences (NASDAQ:CHRS) last issued its quarterly earnings data on Monday, May 8th. The biotechnology company reported ($1.54) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.54). The business had revenue of $0.16 million during the quarter. Coherus BioSciences had a negative return on equity of 827.65% and a negative net margin of 76.85%. Analysts forecast that Coherus BioSciences, Inc. will post ($5.13) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Wells Fargo & Company MN Has $611,000 Stake in Coherus BioSciences, Inc. (NASDAQ:CHRS)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/04/coherus-biosciences-inc-nasdaqchrs-shares-bought-by-wells-fargo-company-mn-updated-updated-updated.html.

A number of research analysts have weighed in on CHRS shares. Maxim Group reduced their target price on Coherus BioSciences from $44.00 to $40.00 and set a “buy” rating for the company in a report on Monday, June 12th. Credit Suisse Group reissued a “buy” rating and set a $38.00 price objective on shares of Coherus BioSciences in a report on Friday, April 21st. Citigroup Inc. set a $38.00 price objective on Coherus BioSciences and gave the stock a “buy” rating in a report on Wednesday, May 17th. J P Morgan Chase & Co reissued a “buy” rating on shares of Coherus BioSciences in a report on Monday, June 12th. Finally, Cowen and Company restated an “outperform” rating and issued a $45.00 target price on shares of Coherus BioSciences in a research report on Tuesday, June 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $37.11.

About Coherus BioSciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Stock Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related stocks with our FREE daily email newsletter.